PE20230301A1 - Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion - Google Patents
Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccionInfo
- Publication number
- PE20230301A1 PE20230301A1 PE2022001743A PE2022001743A PE20230301A1 PE 20230301 A1 PE20230301 A1 PE 20230301A1 PE 2022001743 A PE2022001743 A PE 2022001743A PE 2022001743 A PE2022001743 A PE 2022001743A PE 20230301 A1 PE20230301 A1 PE 20230301A1
- Authority
- PE
- Peru
- Prior art keywords
- polypeptides
- infection
- treat
- development
- limit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977036P | 2020-02-14 | 2020-02-14 | |
| US202063046159P | 2020-06-30 | 2020-06-30 | |
| US202063064235P | 2020-08-11 | 2020-08-11 | |
| PCT/US2021/017799 WO2021163438A1 (en) | 2020-02-14 | 2021-02-12 | Polypeptides, compositions, and their use to treat or limit development of an infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230301A1 true PE20230301A1 (es) | 2023-02-13 |
Family
ID=74873805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001743A PE20230301A1 (es) | 2020-02-14 | 2021-02-12 | Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion |
Country Status (13)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US11192940B2 (en) | 2020-04-10 | 2021-12-07 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus S protein and uses thereof |
| US20220016268A1 (en) * | 2020-07-17 | 2022-01-20 | Tonix Pharmaceuticals Holding Corp. | Skin-based testing for detection of cell-mediated immune responses to sars-cov-2 |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| US20220324918A1 (en) * | 2021-03-30 | 2022-10-13 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF |
| WO2023034991A1 (en) * | 2021-09-02 | 2023-03-09 | Kansas State University Research Foundation | Mrna vaccine formulations and methods of using the same |
| WO2023039540A2 (en) * | 2021-09-10 | 2023-03-16 | Jacobs Technion-Cornell Institute | Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions |
| KR102621026B1 (ko) * | 2021-10-15 | 2024-01-09 | 에스케이바이오사이언스(주) | 단백질의 정제방법 |
| KR102527221B1 (ko) * | 2021-10-15 | 2023-05-02 | 에스케이바이오사이언스 주식회사 | 단백질의 정제방법 |
| KR102524839B1 (ko) * | 2021-11-04 | 2023-04-25 | 에스케이바이오사이언스(주) | 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 |
| US20250000968A1 (en) * | 2021-11-12 | 2025-01-02 | The United States of America, as represented by the Secretary,Department of Health and Human Service | Sars-cov-2 spike fused to a hepatitis b surface antigen |
| WO2023122257A2 (en) * | 2021-12-22 | 2023-06-29 | La Jolla Institute For Immunology | Coronavirus spike glycoprotein with improved expression and stability |
| CN114656571B (zh) * | 2022-02-18 | 2024-07-16 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用 |
| US20240207389A1 (en) * | 2022-04-27 | 2024-06-27 | Northwestern University | Methods for improving covid vaccine immunogenicity |
| KR102689037B1 (ko) * | 2022-07-12 | 2024-07-30 | 에스케이바이오사이언스 주식회사 | SARS-CoV-2 백신 부스터 조성물 |
| KR20250084945A (ko) * | 2022-10-05 | 2025-06-11 | 유니버시티 오브 워싱턴 | 범사르베코바이러스 나노입자 백신 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024218715A1 (en) | 2023-04-19 | 2024-10-24 | Btl Healthcare Technologies A.S. | Culture media based on protein hydrolysate and a process for preparing thereof |
| US12668774B2 (en) | 2023-10-12 | 2026-06-30 | Btl Healthcare Technologies A.S. | Product, system and method of cell cultivation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009016639A2 (en) * | 2007-08-02 | 2009-02-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
| US10248758B2 (en) * | 2013-02-07 | 2019-04-02 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| WO2015080973A1 (en) * | 2013-11-26 | 2015-06-04 | Baylor College Of Medicine | A novel sars immunogenic composition |
| US9630994B2 (en) * | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| WO2017046801A1 (en) * | 2015-09-17 | 2017-03-23 | Ramot At Tel-Aviv University Ltd. | Coronaviruses epitope-based vaccines |
| WO2018175560A1 (en) * | 2017-03-22 | 2018-09-27 | The Scripps Research Institute | Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain |
| EP3606942B1 (en) * | 2017-04-04 | 2025-06-11 | University of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| CN112088014B (zh) * | 2018-02-28 | 2026-03-24 | 华盛顿大学 | 自组装纳米结构疫苗 |
-
2021
- 2021-02-12 EP EP21711980.9A patent/EP4103230A1/en active Pending
- 2021-02-12 CN CN202180028727.9A patent/CN116096404A/zh active Pending
- 2021-02-12 JP JP2022548783A patent/JP7897796B2/ja active Active
- 2021-02-12 MX MX2022009860A patent/MX2022009860A/es unknown
- 2021-02-12 PH PH1/2022/552099A patent/PH12022552099A1/en unknown
- 2021-02-12 WO PCT/US2021/017799 patent/WO2021163438A1/en not_active Ceased
- 2021-02-12 CA CA3167318A patent/CA3167318A1/en active Pending
- 2021-02-12 KR KR1020227031351A patent/KR20220142472A/ko active Pending
- 2021-02-12 AU AU2021221139A patent/AU2021221139A1/en active Pending
- 2021-02-12 BR BR112022016220A patent/BR112022016220A2/pt unknown
- 2021-02-12 PE PE2022001743A patent/PE20230301A1/es unknown
- 2021-02-12 US US17/760,174 patent/US20240277831A1/en active Pending
-
2022
- 2022-08-16 CO CONC2022/0011467A patent/CO2022011467A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4103230A1 (en) | 2022-12-21 |
| WO2021163438A1 (en) | 2021-08-19 |
| MX2022009860A (es) | 2022-11-07 |
| CO2022011467A2 (es) | 2022-10-31 |
| KR20220142472A (ko) | 2022-10-21 |
| BR112022016220A2 (pt) | 2022-10-25 |
| JP2023513720A (ja) | 2023-04-03 |
| JP7897796B2 (ja) | 2026-07-30 |
| PH12022552099A1 (en) | 2024-01-29 |
| CA3167318A1 (en) | 2021-08-19 |
| CN116096404A (zh) | 2023-05-09 |
| US20240277831A1 (en) | 2024-08-22 |
| AU2021221139A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022011467A2 (es) | Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección | |
| ES2562157T3 (es) | Vacuna multiepitópica contra los cánceres asociados con Her2/neu | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| PE20130588A1 (es) | Hepcidina, antagonistas de la hepcidina y metodos de uso | |
| PE20251185A1 (es) | Proteinas de union condicionalmente activadas restringidas | |
| JOP20240283A1 (ar) | تركيبة منظف الشعر وفروة الرأس لإزالة السموم، طرق استخدامها واستخداماتها | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| KR960703942A (ko) | 사람 융모막 고나도트로핀의 항원성을 갖는 화합물(Compounds having the antigenicity of hCG) | |
| CY1113218T1 (el) | Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας | |
| BRPI9911389B8 (pt) | peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo | |
| AR008588A1 (es) | Molecula de acido nucleico aislada que hibridiza con un gen de saliva de pulga, proteina aislada codificada por dicha molecula, composicion terapeuticapara tratar la dermatitis alergica, kit de ensayo para determinar dicha dermatitis, molecula, virus y celula recombinantes, y anticuerpo aislado | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| Mitchell et al. | Localisation of light chain and actin binding sites on myosin | |
| AR035387A1 (es) | Molecula de adn que codifica una udp-glucosa: aglicon-glucosiltransferasa, udp-glucosa: aglicon-glucosiltransferasa, metodo para el aislamiento de una molecula de adnc que codifica una udp-glucosa: aglicon-glucosiltransferasa, metodo para producir udp-glucosa: aglicon-glucosiltransferasa recombinant | |
| GT199800032A (es) | 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas. | |
| AR125379A1 (es) | Un fab anti-tslp con estabilidad mejorada | |
| PE20231442A1 (es) | Proteinas actrii y sus usos | |
| Eckerskorn et al. | In the uncoupling protein from brown adipose tissue the C-terminus protrudes to the c-side of the membrane as shown by tryptic cleavage | |
| CY1105683T1 (el) | Ενεργο συζυγες ακανθοχοιρικης πρωτεϊνης, μεθοδος για την παρασκευη και χρηση αυτου | |
| AR070177A1 (es) | COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL) | |
| ECSP22064620A (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 | |
| AR129441A1 (es) | Péptidos y métodos para el tratamiento del dolor | |
| AR132053A1 (es) | Composiciones para su uso en el tratamiento de clamidia | |
| AR129864A1 (es) | Péptidos y métodos para uso en tratar el dolor | |
| BR112023017163A2 (pt) | Proteína transportadora para antígeno peptídico |